The European Patent Office issues four patents to Nuevolution AB (publ)

Stockholm, 4 March 2016. Nuevolution AB (publ) announces that the European
Patent Office has issued four new patents to Nuevolution.

In the Q2 2015/2016 report, Nuevolution announced that it was expecting three
patents to be granted. Four patents (EP 1905829, EP 2305808, EP 2186897 and EP
1539980) from three different patent families have now issued in Europe.

Nuevolution continues to seek an expansion and strengthening of its patent
position with the means needed and as optimal for the Company. We consider
patents to be an essential element for optimal business development, and for
this reason we invest approximately SEK 7-8 million in patent activities,
supporting our product pipeline and Chemetics® drug discovery platform, each
year.

Nuevolution has invented a technology that allows very large compound
collections (libraries) to be synthesized and screened very efficiently.
Nuevolution uses its platform technology for discovery of new medicines for
treatment of cancer and inflammatory diseases.

Nuevolution’s technology allows each test compound (e.g. a small molecule for
tablet based medicines) to be linked to an oligonucleotide (e.g. DNA), where the
oligonucleotide serves as a barcode holding the information about the structure
of the test compound. This type of barcode allows Nuevolution to work with
compound mixtures holding hundreds of millions to billions of compounds, and to
isolate and identify the biologically active compounds from such complex
mixtures. It enables Nuevolution on a day-to-day basis to screen more than 1,000
times more drug-like molecules than is possible by the largest pharmaceutical
companies with all of their techniques together.

Nuevolution has 11 patent families covering its technology, where patents have
issued from eight of these. With the four new patents issuing, Nuevolution will
hold more than 180 issued patents in various countries. Nuevolution’s previously
granted patents covers different methods for synthesizing libraries and
performing the barcode encoding of libraries, then followed a number of patents
covering composition and structure of the barcode (oligonucleotide). The newly
issued patents cover broad structural classes (e.g. small non-peptide molecules,
scaffolded molecules, macrocyclic molecules etc.) of compounds bound to the
encoding oligonucleotide (barcode).

“The new patents further strengthens Nuevolution’s dominant position in the
technical field by offering a further and important way of protecting the
platform and products that can be derived from it“, said Alex Gouliaev, CEO of
Nuevolution AB (publ), and continued “our strong patent portfolio not only
offers us freedom-to-operate our platform as we do today, but it also limits the
opportunities for others in the technical field.”

For more information, please contact:

Alex Haahr Gouliaev, CEO

Phone: +45 7020 0987

Email: ahg@nuevolution.com

Henrik D. Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company
founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its
proprietary discovery platform and programs with pharmaceutical and
biotechnology companies to seek future benefit of patients in need of novel
medical treatment options. Nuevolution’s internal programs are focused
on therapeutically important targets within inflammation, oncology and immuno
-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein
pursuant to the Securities Markets Act and/or the Financial Instruments Trading
Act. The information was sent for publication on Friday 4 March 2016, 09.00
(CET).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm,
Sweden (ticker: NUE). Västra Hamnen Corporate Finance AB acts as Certified
Adviser to Nuevolution AB (publ). More information about Nuevolution can be
found on: www.nuevolution.com